SynDermix AG is pleased to announce the successful completion of the first SIV for the clinical trial of SDX-3101, in preparation for the recruitment of the first patient to the study. (more…)
Updates
Well beyond tomorrow
First Site Initiation Visit (SIV) Completed for the Clinical Trial of SDX-3101 in Austria 7 January, 2020
Collaboration with King’s College London on the Formulation Development of SDX-21 1 July, 2019SynDermix AG is proud to announce its collaboration with King’s College London for the development of its Nitric Oxide technology. (more…)
AGM 2019: Re-election of Chairman and Board of Directors 11 June, 2019Shareholders approve all proposals put forward by the Board of Directors and re-elect the Chairman and Directors to the board of SynDermix.
(more…)
SynDermix to sell majority stake of SDX-Cosmetics 10 April, 2019SynDermix announces the sale of a majority stake of SDX Cosmetics – formerly a fully owned subsidiary of SynDermix AG. (more…)
SynDermix announces changes to the Executive Team 1 April, 2019The Board of SynDermix announces changes in the management and executive team. (more…)
Share capital increased 14 March, 2019The Board of Directors announces a successful increase of share capital: A total of CHF 1 000 000 in loans were converted against 232 222 newly issued shares.
CHF 10 million Investment 19 December, 2018The Board of SynDermix is pleased to announce the closure of a new investment of CHF 10 million in the Company as of December 2018. The Company plans to use the proceeds to fund operations, product development and future potential acquisitions.
Share capital increased 11 September, 2018The Board of Directors announce a successful increase of share capital: A total of CHF 5 394 135.96 in loans were converted against 1 689 521 newly issued shares.
AGM 2018: Election of New Chairman and Board of Directors 29 June, 2018SynDermix announces the election of a new Chairman and Board of Directors at the Annual General Meeting of 2018. (more…)